Cardiology

Restricted Mean Event-Free Survival Analysis of Statin Discontinuation Versus Continuation in Primary Prevention

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  New England Journal of Medicine https://doi.org/10.1056/NEJMoa2606634
Dr. Nicolas Rodondi et al.

Points

  • International researchers conducted a randomized clinical trial evaluating whether discontinuing primary prevention statins affects major cardiovascular events among one thousand eight hundred eighty multimorbid adults aged seventy and older.
  • Statistical analysis established that the between group difference in restricted mean event free survival time at two years was minus two point zero weeks achieving noninferiority.
  • Over a median follow up of one hundred three weeks nonfatal myocardial infarction nonfatal ischemic stroke or all cause death occurred in twelve point seven percent of discontinuation patients.
  • Serious adverse events occurred in forty three point zero percent of participants assigned to discontinue lipid lowering therapy compared with thirty nine point eight percent in the continuation group.
  • Authors concluded that while statin discontinuation is generally safe and noninferior at two years clinicians should utilize individualized shared decision making rather than applying uniform deprescribing recommendations.

Summary

This randomized clinical trial evaluated whether discontinuing statin therapy for primary prevention affects cardiovascular outcomes in multimorbid older adults without established cardiovascular disease. Published in The New England Journal of Medicine and presented at the American Heart Association Scientific Sessions 2026 by researchers led by Dr. Nicolas Rodondi of the University of Bern and co-author Dr. Rita F. Redberg of the University of California, San Francisco, the study addressed ongoing clinical uncertainty surrounding deprescribing lipid-lowering therapies in geriatric populations. Given that polypharmacy increases adverse drug event risks in older patients, the research sought to determine whether stopping statins is noninferior to continuation regarding time to a first major cardiovascular event.

The trial randomized 1,880 participants aged 70 years and older with at least two chronic conditions and no known cardiovascular disease to either discontinue or continue statin and lipid-lowering therapies. At two years, the between-group difference in restricted mean event-free survival time was -2.0 weeks (P<0.001 for noninferiority). Over a median follow-up of 103 weeks, the composite primary endpoint—nonfatal myocardial infarction, nonfatal ischemic stroke, or death from any cause—occurred in 12.7% of the discontinuation group versus 9.2% of the continuation group. Additionally, at least one serious adverse event was reported in 43.0% of participants who discontinued statins compared with 39.8% of those who continued therapy.

The authors conclude that discontinuing primary prevention statins is statistically noninferior to continuation with respect to major cardiovascular events or all-cause mortality at two years in multimorbid older adults. However, because a small numerical increase in cardiovascular events was observed following deprescribing, clinicians should avoid blanket recommendations and instead engage in individualized shared decision-making with patients when considering statin discontinuation.

Link to the article: https://www.nejm.org/doi/10.1056/NEJMoa2606634 

References

Rodondi, N., Haller, M. L., Bardoczi, J. B., Adam, L., Blum, M. R., Gencer, B., Itach, T., Flury, J. S., Brockhus, L. A., Aebi, P. S., Feller, M., Gregoriano, C., De La Harpe, R., Gussekloo, J., Schwab, N., Poulizac, P., Mooijaart, S. P., Beer, J.-H., Baggio, S., … Trelle, S. (2026). Discontinuing statins in older adults without cardiovascular disease. New England Journal of Medicine, NEJMoa2606634. https://doi.org/10.1056/NEJMoa2606634

About the author

Hippocrates Briefs Team

Leave a Comment